Wilson Sonsini Goodrich & Rosati represented Celest Therapeutics in the transaction. Celest Therapeutics (Shanghai) Co. Ltd (“Celest”) announced a collaboration with Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Boyu Capital in the transaction. The Longreach Group announced that it had, together with the founder family minority shareholders, completed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Beckman Coulter on the deal. Beckman Coulter Diagnostics, a global leader in clinical diagnostics, announced it acquired StoCastic, a leading...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Enliven Therapeutics on the deal. Enliven Therapeutics, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Metacrine on the deal. Equillium, Inc. and Metacrine Inc. announced that the two companies have entered into a definitive merger agreement pursuant to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
You must be a Standard 1 Year member to access this content.
